Impact of extranodal disease burden on survival following CAR-T therapy in relapsed/refractory large B-cell lymphoma: A propensity score-matched multi-center analysis.
Overall survival, CRS, ICANS, and sepsis rates were comparable between extranodal and nodal disease cohorts, and CAR-T therapy as equally effective in extranodal involvement should not influence treatment eligibility decisions.